- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: M.Ratkovi? CROATIA
Co Author(s): R. Lazic I. Boras N. Gabric
Back to previous
To present our results of 4 patients with persistent refractory pseudophakic cystoid macular edema (PCME) treated with Ozurdex (dexamethasone intravitreal implants).
University Eye Hospital Svjetlost, Zagreb, Croatia
4 eyes 6 months after the cataract surgery with chronic PCME refarctory to NSAIDs , and corticosteroid periocular and intraocular injection therapy. 4 eyes were treated with single Ozurdex (dexamethasone intravitreal implant) injection and followed up 1 month, and 3 months after the injection was administered.
Patient 1. Baseline BCVA 0.30 ; macular thickness 403 ?m. 3 months after the injection BCVA 0.65 ; macular thickness 260 ?m. Patient 2. Baseline BCVA 0.25 ; macular thickness 380 ?m. 3 months after the injection BCVA 0.70 ; macular thickness 244 ?m. Patient 3. Baseline BCVA 0.45 ; macular thickness 735 ?m. 3 months after the injection BCVA 0.85 ; macular thickness 289 ?m. Patient 4. Baseline BCVA 0.40 ; macular thickness 562 ?m. 3 months after the injection BCVA 0.70 ; macular thickness 301 ?m. No complications and no significant intraocular pressure increase were observed. 2 patients had mild subconjunctival hyperemia resolved 7 days after Ozurdex injection. 2 patients could see some vitreous opacification 10 days after the injection. 1 patient required limited monotherapy with antiglaucoma eyedrops.
In this small case series Ozurdex sustained-release corticosteroid implant was benefitial in treating patients with chronic refractory PCME. Further larger and randomized clinical trials will investigate efficasy and safety of this treatment.